PBH Prestige Consumer Healthcare Inc. Common Stock

PBH vs. NEOG: Which Stock Is the Better Value Option?

Prestige Consumer Healthcare has seen its share price under pressure over the past year, and that kind of slide naturally puts the spotlight on what investors are paying for its earnings today. The question now is whether the current valuation of Prestige Consumer Healthcare's profit stream still makes sense given how the business is executing. The stock has fallen 24.2% over the past year, which raises the issue of whether the current earnings multiple properly reflects what the company is...

Prestige Consumer Healthcare (PBH) recently outlined medium term targets for fiscal 2027, putting fresh attention on its over the counter portfolio, free cash flow priorities, and the impact of Clear Eyes supply constraints. Prestige Consumer Healthcare’s recent medium term outlook lands after a tougher stretch in the market, with the share price down 23.34% year to date and the 1 year total shareholder return declining 24.25%, while the 30 day share price return has fallen 10.56%. This...

Prestige Consumer Healthcare (NYSE:PBH) said its strategy centers on investing in established over-the-counter brands, maintaining a high-margin operating model and using free cash flow for debt reduction, acquisitions and other shareholder-value initiatives. Speaking at a fireside chat, Chief Fina

PBH vs. NEOG: Which Stock Is the Better Value Option?

Prestige Consumer Healthcare gains from acquisitions, e-commerce growth and strong cash flow, though currency swings and high debt remain key risks.

PBH vs. SYK: Which Stock Is the Better Value Option?

Prestige Consumer Healthcare (NYSE:PBH) closed two acquisitions within three weeks this summer, adding roughly $240 million in annualized revenue to a portfolio anchored by Dramamine and Compound W. The first quarter fiscal 2027 earnings call, held August 6, showed a company beating its own targets even before Breathe Right and LaCorium Health joined the mix. […]

Acquisitions drive 6.5% revenue growth and portfolio diversification.

PBH vs. SYK: Which Stock Is the Better Value Option?

Prestige Consumer Healthcare (NYSE:PBH) reported first-quarter fiscal 2027 revenue growth of 6.5%, supported by broad-based category strength, the initial contribution from its Breathe Right acquisition and retailer order timing. The company raised its reported full-year outlook to incorporate Breat

In early August 2026, Prestige Consumer Healthcare reported fiscal 2027 first‑quarter revenue of US$265.71 million, up from US$249.53 million a year earlier, and raised its full‑year 2027 revenue outlook to US$1.29 billion–US$1.32 billion and projected GAAP diluted EPS of US$4.18–US$4.28, reflecting the addition of the Breathe Right and LaCorium businesses. While recent acquisitions are expected to contribute meaningfully to revenue and earnings, the quarter also showed lower net income and...

Prestige Consumer's Q1 earnings and revenues outpace estimates as acquisitions boost its fiscal 2027 outlook despite margin pressure.

PBH exceeds expectations with 6.5% sales growth, completes Breathe Right integration, and raises full-year EPS guidance.

Moby summary of Prestige Consumer Healthcare Inc.'s Q1 2027 earnings call

While the top- and bottom-line numbers for Prestige Consumer Healthcare (PBH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of +10.11% and +6.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

InfuSystems Holdings (INFU) delivered earnings and revenue surprises of +25.00% and +1.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?